检索结果-南通市图书馆

Adjuvant chemotherapy with gemcitabine plus erlotinib *** alone for patients with resected pancreatic ductal adenocarcinoma:is there a role for erlotinib?—review of the open label phase III trial CONKO 005

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2018年第5期7卷 399-402页

作者： Mathilde Wisniewski Pierre-Alain Placide Sandra Granier Yacoub Al Shatti Shuaib Al Qalaf Mohamed Bouattour Michele Lamuraglia pascal hammel Department of Digestive and Medical Oncology Hopital Beaujon(AP-HP)University Denis Diderot-ParisⅦClichyFrance

Sinn et al. (1) report the results of a multicenter trial comparing the combination of gemcitabine and erlotinib with gemcitabine alone for adjuvant therapy in 436 patients who underwent R0 resection for pancreatic du... 详细信息

关键词： gemcitabine patients ductal

Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2019年第34期25卷 5082-5096页

作者： Diane Lorenzo Vinciane Rebours Frédérique Maire Maxime Palazzo Jean-Michel Gonzalez Marie-Pierre Vullierme Alain Aubert pascal hammel Philippe Lévy Louis de Mestier Pancreatology Department Beaujon HospitalAssistance Publique-Hopitaux de ParisClichyand Paris Diderot UniversityParis 75013France INSERM UMR1149Paris 92110France Departement of Gastroenterology Aix Marseille university-APHM-Hopital NordMarseille 13000France Radiology Department Beaujon HospitalAssistance Publique-Hopitaux de ParisClichyand Paris Diderot UniversityParis 92110France Oncology Department Beaujon HospitalAssistance Publique-Hopitaux de ParisClichyand Paris Diderot UniversityParis 92110France

Managing familial pancreatic cancer(FPC)is challenging for gastroenterologists,surgeons and ***-risk individuals(HRI)for pancreatic cancer(PC)(FPC or with germline mutations)are a heterogeneous group of subjects with a theoretical lifetime cumulative risk of PC over 5%.Screening is mainly based on annual magnetic resonance imaging(MRI)and endoscopic ultrasound(EUS).The goal of screening is to identify early-stage operable cancers or high-risk precancerous lesions(pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasms with high-grade dysplasia).In the literature,target lesions are identified in 2%-5%of HRI who undergo *** appears to provide better identification of small solid lesions(0%-46%of HRI)and chronicpancreatitis-like parenchymal changes(14%-77%of HRI),while MRI is probably the best modality to identify small cystic lesions(13%-49%of HRI).There are no specific studies in HRI on the use of contrast-enhanced harmonic *** can also be used to obtain tissue ***,there is still limited evidence on the accuracy of imaging procedures used for screening or agreement on which patients to *** cost-effectiveness of screening is also *** new EUS-related techniques,such as searching for DNA abnormalities or protein markers in pancreatic fluid,appear to be promising.

关键词： Endoscopic ultrasound Familial pancreatic cancer Fine-needle aspiration Intraductal papillary mucinous neoplasm Pancreatic cancer Pancreatic intraepithelial neoplasia Pancreatic cancer screening guidelines

Gemcitabine in elderly patients with advanced pancreatic cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2011年第30期17卷 3497-3502页

作者： Olivia Hentic Vinciane Rebours Philippe Lévy Philippe Ruszniewski pascal hammel Magaly Zappa Chantal Dreyer Eric Raymond Ple des maladies de l'Appareil Digestif Service de PancréatologieHpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance Ple des maladies de l’Appareil Digestif Service de PancréatologieHpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance Service de Radiologie Hpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance Service de Cancérologie Hpital Beaujon100 boulevard du général Leclerc92110 ClichyFrance

AIM： TO assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS： All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were： performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care （BSC）. RESULTS： Thirty-eight patients （53% women, median age 78 years, range 75-84） with pancreatic cancer （metastatic： n = 20, locally advanced： n = 18） were studied. Among them, 30 （79%） were able to receive chemotherapy [median number： 9 infusions （1-45）]. Six patients （23%） had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients （11%） had a partial tumor response, 13 （46%） had a stable disease and 12 （43%） had a tumor progression. Median survival was 9.1 mo （metastatic： 6.9 too, locally advanced： 11.4 too）. CONCLUSION： Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.

关键词： Elderly Pancreas Cancer Gemcitabine

FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第33期18卷 4533-4541页

作者： Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet pascal hammel Service de Gastroentérologie-Pancréatologie Hpital Beaujon 100 Boul-evard du Général Leclerc 92110 Clichy La Garenne AP-HP France Service d'Oncologie Médicale Hpital Saint Antoine 184 Rue du Faubourg Saint-Antoine 75012 Paris AP-HP France Unité de Biostatistique et d'Epidémiologie EA 4184 Centre Georges Franois Leclerc 1 Rue du Pr Marion 21079 Dijon France Service d'Oncologie Médicale Hpital Beau-jon 100 Boulevard du Général Leclerc 92110 Clichy La Garenne AP-HP France Département d'Oncologie Médicale Institut Mutualiste Montsouris 42 Boulevard Jourdan 75014 Paris France

AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated w

关键词： Pancreatic cancer Pancreatic adenocarcinoma Metastases Chemotherapy 5-fluorouracil Irinotecan Camptothecin FOLFIRI regimen

奥拉帕利用于胚系BRCA基因突变型转移性胰腺癌一线铂类化疗后的维持治疗

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

肝胆外科杂志 2020年第3期28卷 166-166页

作者：濮天(摘译) 赵义军(审校) Talia Golan pascal hammel From the Oncology Institute Sheba Medical Center Tel Aviv University Tel Aviv Israel (T.G.) Hôpital Beaujon (Assistance Publique-Hôpitaux de Paris) Clichy and University Paris VII Paris (P.H.) IRCCS Ospedale San Raffaele Scientific Institute Milan (M.R.) Azienda Ospedaliera Universitaria Integrata Verona Verona (G.T.) and Fondazione Policlinico Universitario Gemelli IRCCS Rome (G.T.) - all in Italy University Hospitals Gasthuisberg and KU Leuven Leuven Belgium (E.V.C.) Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology Barcelona (T.M.) Fox Chase Cancer Center Philadelphia (M.J.H.) Samsung Medical Center Sungkyunkwan University School of Medicine (J.-O.P.) and Seoul National University Hospital Cancer Research Institute Seoul National University College of Medicine (D.-Y.O.) - both in Seoul South Korea University College London Cancer Institute London (D.H.) and AstraZeneca Cambridge (D.M.) - both in the United Kingdom Asklepios Tumorzentrum Hamburg Asklepios Klinik Altona Hamburg (D.A.) St. Josef-Hospital Ruhr University Bochum Bochum (A.R.-S.) and Klinikum rechts der Isar Department of Internal Medicine II Technische Universität München Munich (H.A.) - all in Germany Memorial Sloan Kettering Cancer Center New York (E.M.O.) AstraZeneca Gaithersburg MD (K.Y.C. G.Y.L.) Merck Kenilworth NJ (K.S.) and the University of Chicago Chicago (H.L.K.).

胰腺癌的分子靶向治疗探索之路充满挑战且收获甚微,直至本次POLO (Pancreas Cancer Olaparib Ongoing)研究结果发表在新英格兰杂志。奥拉帕利(olaparib)也被NCCN指南推荐用来治疗BRCA突变型胰腺癌。BRCA基因突变除了与卵巢癌及乳腺癌发... 详细信息

胰腺癌的分子靶向治疗探索之路充满挑战且收获甚微,直至本次POLO (Pancreas Cancer Olaparib Ongoing)研究结果发表在新英格兰杂志。奥拉帕利(olaparib)也被NCCN指南推荐用来治疗BRCA突变型胰腺癌。BRCA基因突变除了与卵巢癌及乳腺癌发病有关外,还可导致胰腺癌的发病风险也明显增加。

关键词：分子靶向治疗维持治疗发病风险新英格兰胰腺癌铂类化疗奥拉卵巢癌